Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: Toronto
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

Theratechnologies Inc

+ Add to Watchlist

TH:CN

1.3600 CAD 0.0400 2.86%

As of 15:59:58 ET on 04/24/2015.

Snapshot for Theratechnologies Inc (TH)

Open: 1.3500 Day's Range: 1.3000 - 1.4000 Volume: 740,270
Previous Close: 1.4000 52wk Range: 0.3250 - 1.4900 1-Yr Rtn: +216.28%

Stock Chart for TH

No chart data available.
  • TH:CN 1.3600
  • 1D
  • 1M
  • 1Y
1.4000
Interactive TH Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for TH

Current P/E Ratio (ttm) -
Estimated P/E(11/2015) 45.3333
Relative P/E vs. SPTSX -
Earnings Per Share (CAD) (ttm) -0.1272
Est. EPS (CAD) (11/2015) 0.0300
Est. PEG Ratio -
Market Cap (M CAD) 82.97
Shares Outstanding (M) 61.01
30 Day Average Volume 654,503
Price/Book (mrq) 10.9249
Price/Sale (ttm) 8.6153
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 07/09/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for TH

  • Revenue
  • Net Income (M/CAD)
  • Profit Margin (%)

Company Profile & Key Executives for TH

Theratechnologies, Inc. is a specialty pharmaceutical company that discovers and develops therapeutic peptide products, with an emphasis on growth-hormone releasing factor peptides. The Company's main product is being marketed in the United States for the reduction of excess abdominal fat n HIV-infected patients with lipodystrophy.

Luc TanguayPres/CEO/Investor RelationsLyne FortinSenior VP/Chief Commercial Ofcr
Christian MarsolaisSenior VP:Scientific AffairsMarie-Noel ColussiVP:Finance
More Company Profile & Key Executives for TH

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil